SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

BCMA, CAR-T

September 15, 2023

KarMMa-9 Trial Design Disclosed; Plans to Accelerate Cell Therapy Development in Multiple Autoimmune Diseases; Innovative and Diverse Preclinical Pipeline Presented; BMS’s 2023 R&D Day Summary

Here is a brief preview of this blast: On Thursday, September 14, BMS held its 2023 R&D day (press release / presentation) disclosing Abecma’s (BMS / 2seventy’s BCMA CAR-T) Ph3 KarMMa-9 trial design in HR NDMM. The company also highlighted its plans to initiate BMS-986393’s (CC-95266; GPRC5D CAR-T) registrational trial in H1 2024 as well as its intention to submit an IND for the investigation of BMS-986353 (CC-97540 CD19 NEX-T CAR-T) in multiple sclerosis (MS) in September 2023. Additionally, BMS shared its full cell therapy pipeline, including highly innovative and diverse preclinical assets. Below, Celltelligence provides insights on KarMMa-9 design and the company’s new GPRC5D x BCMA dual targeting CAR-T for MM, while discussing BMS’s market opportunity in the autoimmune disease cell therapy space.